GW Pharmaceuticals to Present at Upcoming Investor Conferences
Justin Gover, GW’s Chief Executive Officer, will present at two upcoming conferences.
Read More
Category: UK Stocks
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
Cannabidiol oral solution is recommended as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome.
Read More GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019
Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million.
Read More GW Pharmaceuticals to Present at Upcoming Investor Conferences
Stephen Schultz, GW’s Vice President of Investor Relations, will present at two upcoming conferences.
Read More GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019
GW Pharmaceuticals is the world leader in the development and commercialization of cannabinoid prescription medicines.
Read MoreGET LISTED
